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Abstract: In physiological hemostasis a prompt recruitment of platelets on the vessel damage 
prevents the bleeding by the rapid formation of a platelet plug. Qualitative and/or quantitative 
platelet defects promote bleeding, whereas the high residual reactivity of platelets in patients 
on antiplatelet therapies moves forward thromboembolic complications. The biochemical 
mechanisms of the different phases of platelet activation – adhesion, shape change, release 
reaction, and aggregation – have been well delineated, whereas their complete translation 
into laboratory assays has not been so fulfilled. Laboratory tests of platelet function, such 
as bleeding time, light transmission platelet aggregation, lumiaggregometry, impedance 
aggregometry on whole blood, and platelet activation investigated by flow cytometry, are 
traditionally utilized for diagnosing hemostatic disorders and managing patients with platelet 
and hemostatic defects, but their use is still limited to specialized laboratories. To date, a 
point-of-care testing (POCT) dedicated to platelet function, using pertinent devices much 
simpler to use, has now become available (ie, PFA-100, VerifyNow System, Multiplate 
Electrode Aggregometry [MEA]). POCT includes new methodologies which may be used in 
critical clinical settings and also in general laboratories because they are rapid and easy to 
use, employing whole blood without the necessity of sample processing. Actually, these dif-
ferent platelet methodologies for the evaluation of inherited and acquired bleeding disorders 
and/or for monitoring antiplatelet therapies are spreading and the study of platelet function 
is strengthening. In this review, well-tried and innovative platelet function tests and their 
methodological features and clinical applications are considered.
Keywords: platelets, method, point-of-care testing, laboratory assessment, bleeding, 
thrombosis
Introduction
Human platelets are critically involved in both normal hemostasis and pathological 
bleeding and thrombosis. These particular cells contribute greatly to vessel constriction 
and repair, host defense, and tumor growth/metastasis.1 In addition, platelets acting 
together with other cells – white, endothelial, or smooth muscle cells – play a part 
in inflammation, in related pathologies, and in the promotion of atherosclerosis.2–4 
Notwithstanding this multiplicity of roles, the available platelet function tests explore 
principally the alterations directly related to the hemostatic process.5
Primary hemostasis consists of the interaction between platelets and vessel wall. 
At the site of damage of a vessel wall, platelets are rapidly engaged in a sequential 
functional response including various steps in platelet activation: adhesion, spread-
ing, shape change, aggregation, release reaction, exposure of a procoagulant surface, 
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and clot retraction. The rapid progression of these different 
capacities causes the activated platelets to form a hemostatic 
plug that occludes the site of injury to prevent blood loss.6 
An increased risk of bleeding could be present when platelet 
count is reduced and/or one of their functions is defective. 
Conversely, improper thrombus formation could be due to a 
growth in platelet count or reactivity. In particular, activated 
platelets adhere and aggregate within atherosclerotic lesions, 
forming occluding arterial thrombi that may result in throm-
boembolic disease such as stroke or myocardial infarction, 
two of the major causes of morbidity and mortality in the 
Western world.4,7
These different functions of platelets may be reliably 
detected with a wide spectrum of tests. The inherited or 
acquired platelet dysfunctions have to be essentially diag-
nosed because a rapid identification of patients at risk of 
bleeding is really necessary; the monitoring of antiplatelet 
therapy is becoming increasingly important for the identi-
fication of hypo- or hyperresponder patients at risk of both 
thrombosis or hemorrhage; the management of periopera-
tive hemostasis and the different aspects of platelet banking 
(concentrates, transfusions, and evaluation of donor platelet 
function) is of vital importance; and – last but not least – the 
physiopathology of platelets should be critically recognized 
by basic research with these tests.8,9
The history of platelet function testing (PFT) begins 
with the development of the evaluation of the bleeding time 
(BT) by the Duke procedure.10 This was the first test for the 
assessment of the capacity of platelets to form a plug. For 
many years, it has been the unique screening test to iden-
tify both congenital or acquired platelet disorders.11 In the 
1960s, the revolutionary platelet aggregation test in platelet-
rich plasma (PRP) – ie, light transmission aggregometry 
(LTA) –  according to Born’s studies was the key method 
used to diagnose platelet function.12 In this test, the ability 
of platelets to aggregate to each other in response to external 
aggregating agents – agonists, such as adenosine-diphosphate 
(ADP), arachidonic acid (AA), collagen, and epinephrine 
(EPI) – is measured in vitro.13 Since the late 1980s, other PFT 
methods, such as platelet aggregometry in whole blood (WB), 
the study of activated platelets ex vivo by flow cytometry, the 
measurement of specific compounds released by platelets, 
and the assessment of platelet nucleotides have become 
available.14–16 Hence, PFT has been narrowly employed for 
the diagnosis and management of patients suffering from 
hemorrhagic problems.17 In the last 2 decades, the clini-
cal application of PFT has improved as it has increasingly 
come to be used for monitoring the antiplatelet treatment of 
cardiovascular patients at risk of arterial disease.18 However, 
the increasing number of patients on antiplatelet drugs, 
with a higher risk of bleeding, especially during trauma and 
surgical procedures, has also led to the emergence of PFT 
as a useful tool in presurgical/perioperative settings for the 
prediction of hemorrhage and for monitoring the efficacy of 
different prohemostatic therapies. In this scenario, the devel-
opment of new, simpler instruments for assessing platelet 
function at the point-of-care (POC) or bedside has led to 
better prospects of using PFT not only in specialized clinical 
or research laboratories, but also in general laboratories and 
in different clinical settings.9,18,19
This review aims to describe the current status of avail-
able PFT that employs laboratory methodologies and point-
of-care testing (POCT) with the pertinent instrumentation 
for different clinical settings. Different methodologies are 
employed both in the diagnosis of inherited and acquired 
bleeding disorders and in the monitoring of residual platelet 
reactivity of patients on antiplatelet treatment.
Platelet function methods
In recent years, the assessment of platelet (dys)function 
has become increasingly necessary in a variety of clinical 
settings: 1) for the identification of patients with bleeding 
disorders; 2) for monitoring the response to antiplatelet 
treatment; 3) in the evaluation of perioperative hemostasis; 
and 4) in transfusion medicine. Because there are diverse 
employment fields in which platelet function is studied and 
the platelets present a plethora of functions, different meth-
odologies have been developed. Indeed, the platelet methods 
are based on different operating principles, and few assays 
are able to investigate “all in one device” platelet activation 
pathways. The different modalities of devices to operate 
may be based on the assessment of platelet adhesion and 
aggregation, on the submission of platelets under special 
shear conditions, on the analysis of physical properties of 
clot, and on the measurement of platelet compounds.8,9 In 
addition to the wide set of assays and devices for studying 
platelet function, because platelets are cells that may be 
easily activated during the blood sampling, a number of 
preanalytical variables can produce platelet artifacts affect-
ing the different platelet functions. Therefore, a high degree 
of experience and expertise is necessary to perform and 
interpret PFT. In this sense, this review attempts to make a 
comparison of the various platelet function methodologies 
on the basis of the same principle that both are laboratory 
tests or POCT. The different platelet function tests reported 
in this review are grouped by the various methodological 
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principles in Table 1, and the pros and cons of some platelet 
tests are documented in Table 2.
Bleeding time
BT is the first test designed for evaluating in vivo primary 
hemostasis.10 BT assesses the platelet ability to develop a 
hemostatic plug by recording the time that the platelets take to 
occlude an in vivo skin wound for stopping the hemorrhage.20 
Although the technique is easy and quick to perform without 
any WB processing, it is influenced by different variables 
such as differences in skin thickness and temperature among 
patients and an incorrect management of the test procedure. 
Nevertheless, the use of available devices to standardize the 
test, a lack of accuracy, and unclear association with clini-
cal patient state persist. No study has clearly established the 
ability of BT evaluation to predict the risk of bleeding in 
patients, and a study only reported that BT could predict 
clinical bleeding in patients with acute myocardial infarc-
tion undergoing thrombolytic therapy.21,22 Moreover, this 
test is not used routinely to monitor the effect of antiplatelet 
therapy.23 Nevertheless, BT is still regarded as a screening 
test to identify both congenital and acquired disorders of 
primary hemostasis in those laboratories that do not perform 
other platelet function tests.
Tests based on platelet aggregation
Light transmission platelet aggregometry  
on platelet-rich plasma
LTA, designed by Born in the 1960s, is performed by using the 
PRP as milieu.12,24 It is still deemed the gold standard test for the 
Table 1 Different methodologies for assessment of platelet function
Method Sample Method application Method principle
Bleeding time Native wB Screening test (obsolete) in vivo measurement of bleeding block
Tests based on platelet aggregation
Light transmission platelet  
aggregation (LTA)
Citrated PRP Screening test for bleeding tendency 
Diagnostic for platelet defects 
Monitoring antiplatelet treatment effect
Photo-optical measurement of light 
transmission increase in relation  
to agonist-induced platelet aggregation
impedance platelet aggregation Citrated wB Screening test for bleeding tendency 
Diagnostic for platelet defects 
Monitoring antiplatelet treatment effect
Measurement of electrical impedance 
increase in relation to agonist-induced 
platelet aggregation
Lumiaggregometry Citrated wB Detection of storage/release disorders LTA or wB aggregometry combined  
with luminescence
Plateletworks Citrated wB Monitoring of the platelet response  
to antiplatelet agents
Platelet counting pre- and postactivation  
in whole blood
Tests based on platelet adhesion under shear stress
PFA-100; innovance PFA-200 Citrated wB Assessment of bleeding risk and drug effects 
Searching severe platelet dysfunctions,  
revealing of VwD
Time evaluation of high shear WB flow  
blocked by platelet plug into a hole  
in activated surface
impact; Cone and Plate(let)  
Analyzer
Citrated wB Screening of primary hemostasis Shear-induced platelet adhesion–aggregation 
upon specific surface
Global thrombosis test (GTT) Native wB evaluation of platelet function  
and thrombolysis
Measurement of time cessation of wB  
flow by high shear-dependent platelet plug  
formation
Platelet function methods combined with viscoelastic test
TeG/platelet mapping system Citrated wB Assessment of global hemostasis plus  
monitoring antiplatelet treatments effect
evaluation of rate of clot formation  
based on low shear-induced and agonist  
addition
ROTeM platelet Citrated wB Assessment of global hemostasis plus  
diagnostic of platelet defects plus  
monitoring antiplatelet treatments effect
Measurement of electrical impedance  
increase in relation to agonist-induced 
platelet aggregation
Platelet analysis based on flow cytometry
Flow cytometry Citrated wB,  
PRP, w-Plt
Cell counting, detection platelet activation  
by extent of expression of surface and/or  
cytoplasmic biomarkers
engineering laser-based detection  
of suspending fluorescent label platelets  
in a flowing solution
Evaluation of Thromboxane metabolites
Radio- or enzyme-linked  
immune assays
Serum, urine,  
citrated Pls
Measurement of TxA2 metabolites  
(and Beta-TG, PF4, soluble P-selectine)a
Ligand-binding assays
Note: aNot planned in this review.
Abbreviations: Beta-TG, beta-thromboglobulin; Pls, plasma; PRP, platelet-rich-plasma; ROTeM, rotational throm boelastometry; TeG, thromboelastography; TxA2, thromboxane A2; 
wB, whole blood; w-Plt, washed platelets; VwD, Von willebrand disease.
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Table 2 Pros and Cons of reviewed platelet function tests
Method Pro Contra
Bleeding time in vivo test, quick 
No wB processing
invasive 
Poorly standardized 
Dependent on many variables  
(skin thickness, and temperature operator’s skills)
Light transmission platelet  
aggregation (LTA)
Historical gold standard 
Diagnostic method 
Flexible 
Different platelet pathways investigated 
Sensitive to anti-plt therapy
Manual sample processing 
Pre- and analytic variables 
High sample volume 
Time-consuming
impedance Platelet Aggregometry No sample processing 
Diagnostic method 
Flexible 
Different platelet pathways investigated 
Sensitive to anti-plt therapy 
Close to POCT (multiple system)
Limited HCT and platelet count range
VerifyNow system waived POCT 
No wB processing 
easy, quick
Nonflexible 
Very expensive 
Monitoring antiplatelet therapy 
Limited HCT and platelet count
Plateletworks POC system 
Minimal sample preparation 
easy, rapid screening test
indirect assay 
Required adjunctive platelet count 
Scarce data
PFA-100; innovance PFA-200 in vitro standardized BT 
easy, quick POCT 
Sensitive to severe platelet defects
Rigid closed system 
Platelet count – HCT-dependent 
Not sensitive to platelet secretion defects.
impact Cone and Plate(let) Analyzer wB assay 
Global platelet method 
Small sample volume
expensive 
experienced staff 
Lack of clinical studies 
Not widely available
Global thrombosis test (GTT) wB assay 
Global platelet method 
Small sample volume
Lack of clinical studies 
Not widely available
TeG platelet mapping POCT 
Global hemostasis test 
Reduces blood transfusions
Measure clot properties 
More studies are needed
ROTeM platelet POCT 
Predicts bleeding 
Reduces blood transfusions 
improves clinical outcome 
Global hemostasis test  
wB platelet aggregometry
Limited HCT and platelet count range (for 
platelet system) 
Lack of clinical studies
Abbreviations: BT, bleeding time; HCT, hematocrit; plt, platelet; POC, point-of-care; POCT, point-of-care testing; ROTeM, rotational throm boelastometry; TeG, 
thromboelastography; wB, whole blood.
assessment of the various platelet functions. Indeed, by adding a 
wide panel of agonists to PRP, a considerable amount of data are 
obtained about the various pathways of platelet activation.13
This test assesses in vitro the platelet-to-platelet clump 
formation in a glycoprotein (GP) IIb/IIIa-dependent manner, 
ie, the aggregation, the most important function of platelets. 
The assay is based on the measurement of the increase in 
light transmission through the optically dense sample of PRP 
after the addition of the exogenous platelet agonist. During 
the assay, the PRP after the addition of agonist becomes 
clearer because of the precipitation of platelet aggregates. 
This determines an increase in light transmission through the 
plasma sample. The device records the rate and maximal per-
centage of this increase from 0% (maximal optical density of 
PRP) to 100% (no optical density of autologous platelet-poor 
plasma) by a photometer. This signal is converted automati-
cally in a graphic curve that parallels the increase in light 
transmission during the platelet aggregation (Figure 1). The 
available aggregometers are easy-to-use devices equipped 
with automatic setting (100% and 0%), software for storing 
results and disposable cuvettes with a stirring bar. The slope 
of the curve, the maximal extent of aggregation (%), and the 
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latency time (lag phase) are the parameters automatically 
measured, and the shape change and primary and secondary 
aggregation may be seen graphically. To the PRP sample, 
different agonists are added to stimulate different platelet 
activation pathways, obtaining information about the several 
features of platelet function.
Born’s platelet aggregometry is the most widely employed 
methodology for detecting platelet function disorders 
and monitoring antiplatelet therapies. Actually, it is deemed 
the first step in the flowchart for the study of hemorrhagic 
patients with inherited or acquired platelet dysfunctions.25–29 
At the first sign of congenital/acquired bleeding disorders, 
in addition to the most commonly used agonists ADP, 
AA,  collagen, and epinephrine, other agonists should be 
employed: thrombin receptor activating peptide (TRAP), 
Thromboxane A2 (TXA2) mimetic U46619,  calcium 
 ionophore A23187. The antibiotic ristocetin is another agent 
used as agonist in the assessment of platelet function. It 
facilitates the binding of Von Willebrand Factor (VWF) to 
the glycoprotein Ib/IX/V complex. Different concentrations 
of ristocetin are used: this way of dose–response allows one 
to investigate both increased and decreased sensitivity to 
ristocetin. For a normal result, both functional VWF and 
 normal glycoprotein Ib/IX/V complex must be present. 
Hence, ristocetin-induced platelet aggregation is considered 
a test that can detect both VW disease and platelet dysfunc-
tions such as Bernard–Soulier syndrome.29
Monitoring antiplatelet therapies (eg, aspirin and thienopyri-
dine) by using LTA has permitted the prediction of major adverse 
cardiovascular events (MACE) in cardiovascular patients at high 
risk. The rate of residual platelet reactivity defined by ADP-, 
AA-LTA, or both has been associated with the development 
100
50
0
100
50
0
100
50
0
100
50
0
2 µmoI/L ADP
0 50 100 150 200 250 300 350
0 50 100 150 200 250 300 350
0 50 100 150 200 250 300 350
10 µmoI/L ADP
5 µmoI/L epinephrine
2 µg/mL collagen
Time (s) Time (s)
1 mmoI/L arachidonic acid
1.5 mg/mL ristocetin
0 50 100 150 200 250 300 350
0 50 100 150 200 250 300 350
0 50 100 150 200 250 300 350
A
g
g
re
g
at
io
n
 (
%
)
100
50
0
A
g
g
re
g
at
io
n
 (
%
)
100
50
0
A
g
g
re
g
at
io
n
 (
%
)
A
C
E
B
D
F
Figure 1 Light transmission platelet aggregation tracings from a healthy subject in response to different agonists.
Note: (A–F) Final concentrations are reported.
Abbreviation: ADP, adenosine-diphosphate.
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of ischemic events both in acute coronary syndrome (ACS) 
patients and in those with stable coronary artery disease. Not 
only the previous evaluation of degree of platelet inhibition in 
stable cardiovascular artery disease (CAD) patients, but also 
the laboratory and clinical research of a cut-off value for ADP 
and/or AA-induced platelet aggregation have been instrumental 
in identifying those ACS patients who are nonresponders to 
antiplatelet agents and are at high risk of MACE.30–33
Although LTA is accepted as the most important and 
complete assay that clinical laboratories can perform to 
diagnose platelet function disorders, this assay presents some 
peculiar problems. Indeed, the technique may be affected by 
different preanalytical conditions (ie, type of anticoagulant, 
lipid plasma, hemolysis, or low platelet count), and by different 
procedural conditions (ie, PRP preparation, use of different con-
centrations of agonists), and the laboratory staff should have a 
high degree of skill, experience, and expertise in performing and 
interpreting platelet function. Hence, this method is constantly 
verified by an ongoing standardization process,25,34,35 and recent 
specific guidelines for LTA aimed at stabilizing/normalizing 
the correct procedure have been published.36–39
Finally, LTA test is the first diagnostic step in the evalua-
tion of platelet disorders as reported by different studies.25,28 
Because platelet dysfunction may be caused by a plethora 
of factors, for achieving a diagnostic hypothesis, the results 
obtained by LTA should be confirmed by further specific tests. 
By using flow cytometry analysis for the identification of 
expression of specific platelet components and lumiaggrego-
metry for the identification of impaired platelet secretion or the 
Platelet Function Analyzer-100 (PFA-100) system, performed 
as a second diagnostic, LTA as a first-step diagnostic tool can 
be specifically confirmed.28
impedance whole blood aggregometry
Impedance whole blood aggregometry (WBA) allows one to 
assess platelet function by using the anticoagulated WB as 
milieu without any sample processing.40 It is based on the prin-
ciple that activated platelets stick via their surface receptors 
to artificial surfaces of two electrodes within the WB sample 
positioned at a determined distance between them. Platelet 
aggregation is assessed by detecting the increase in electrical 
impedance generated by the aggregation of other platelets 
upon those fixed to the electrodes. Hence, by diminishing 
the current intensity, the electrical impedance increases. The 
degree of the increase in impedance is recorded in Ohms.14
By the utilization of WB aggregometry, platelet function 
is assessed under more physiological conditions given that 
the contributions of other blood elements also may affect 
platelet function. Another key aspect is that WB aggrego-
metry takes place on surfaces, which enables this assay to 
be more adherent to the actual capacity of platelets to adhere 
and aggregate upon a solid phase. Moreover, WBA presents 
two important advantages: 1) use of a small quantity of WB 
in which all subpopulations of platelets are present; 2) no 
manipulation of the sample without activation of platelets, 
resulting in a rapid analysis of platelet function.
Now, the Multiple Electrode Aggregometry (MEA) 
is a new methodology by which the WB platelet aggrega-
tion can be assessed by using a new pertinent device that 
allows one to consider this assay as a POCT.41 Recently, this 
new aggregometer (Multiple Platelet Function Analyzer – 
 Dynabyte – Roche Diagnostics, Mannheim, Germany) has 
become available across the world. The device presents par-
ticular features that make it a valid tool for rapid and complete 
platelet function evaluation. It is a five-channel computerized 
instrument equipped with disposable cuvettes ready to use 
with two independent sensor units and an automated pipetting. 
The reagents – agonists and diluents – are ready to use. The 
platelet aggregation is simultaneously measured in duplicate 
by using each sensor unit separately and calculated auto-
matically as area under curve (AUC). With these important 
advantages MEA has acquired a high clinical value like that 
of LTA, and the use of different agonists similar to those used 
for LTA has made it suitable for the diagnosis of bleeding 
diathesis and for monitoring antiplatelet therapies, defining 
cut-off values to discriminate cardiovascular patients with 
high on-treatment platelet reactivity.42–49 MEA has been used 
to study the occurrence of VWD in patients with severe aortic 
stenosis and, on the other hand, the high thrombotic risk due 
to heparin-induced thrombocytopenia (HIT).50,51
In addition, MEA has not only been able to identify 
cardiovascular patients not responding to antiplatelet agents 
and at risk of MACE, but has been considered a skill assay 
to distinguish those patients with a high inhibition of platelet 
function and at risk of bleeding.52–54 Ranucci et al55 reported 
that investigating platelet function by using MEA before 
cardiac surgery has made it possible to identify the hyper-
responder patients at risk of postoperative bleeding. Recently, 
it was reported that low extent of TRAP-induced platelet 
aggregation by MEA was defined as a factor independently 
associated with intramyocardial hemorrhage in patients with 
myocardial infarction.56 Actually, multiple evidence reveals 
that MEA might be able to identify pre-/postoperatively those 
patients at risk of blood loss. Hence, this platelet function test 
has been proposed as a rapid and useful tool for the manage-
ment of postoperative severe bleeding.56–58
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MEA, overcoming the traps that LTA presents, may 
allow the rapid assessment of the platelet function with-
out the requirement of a specialized laboratory. This POC 
system requires minimal technical knowledge and training 
to perform accurately, the working steps are automatically 
accomplished and easily controlled, and only interpretation 
data and judgment are required. Probably, in the future this 
test will be able to have a similar clinical value as of LTA 
with the advantage of its use in general laboratories.
Lumiaggregometry
Lumiaggregometry allows simultaneous measurement of the 
release of adenine nucleotides from platelet granules and 
platelet aggregation.16,59–61 The method is based on the evalua-
tion of adenosine triphosphate (ATP) released from activated 
platelets by different agonists by using a luminescence tech-
nique in PRP, washed platelets (WP), or WB.62–65 The assay 
is based on the conversion of ADP, released from the plate-
let dense granules, to ATP that reacts with the luciferin– 
luciferase reagent. The light emitted, proportional to the ATP 
concentration, is quantified by the lumi-aggregometer. This 
technique is used for evaluating specific deficiencies in the 
number and content of dense granules: the so-called storage 
pool defects or specific defects in degranulation.8,9,62–65 As 
with LTA, this analysis might be used as a first screening test 
of patients with clinical suspicion of platelet function defects 
such as abnormalities of platelet granule secretion and/or 
content, plasma membrane receptor defects, and to evaluate 
platelet functions during thrombocytopenia.28,66,67
VerifyNow system
The VerifyNow system (ITC, Edison, NJ, USA) is a platelet 
function-waived POCT consisting of a device that assesses 
in WB platelet aggregation by a turbidimetric-based optical 
detection and using a system cartridge containing fibrinogen-
coated beads and platelet agonists.68 The method is based 
on the capacity of activated platelets to bind to fibrinogen: 
platelets aggregate upon the fibrinogen-coated beads within 
the assay cartridge in proportion to the number of activated 
GPIIb/IIIa receptors. The crossing WB optical signal increases 
as the activated platelets aggregate to the fibrinogen attached 
to the spheres. The use of this closed system requires no blood 
manipulation and instrument handling: actually, the method-
ology is very waived and it is largely employed to  monitor 
antiplatelet therapies in the emergency cardiac operating room 
without the help of a specialized laboratory.54 Formerly, the 
method (called Ultegra) was used to verify the inhibitory effect 
of platelet GPIIb/IIIa antagonists (abciximab or eptifibatide) 
in cardiovascular patients undergoing percutaneous coronary 
intervention (PCI): in this assay (VerifyNow IIb/IIIa Test), 
the thrombin receptor activating peptide (iso-TRAP) is used 
as agonist to maximally stimulate platelet aggregation.69 The 
device reports patient results as Platelet Aggregation Units 
(PAU) calculated as rate and degree of aggregation. Now, two 
more assays each sensitive to targeted drugs are  available: 
Aspirin Test with AA as agonist (sensitive to aspirin therapy), 
whose results are expressed as Aspirin  Reaction Units (ARU); 
and PRUTest (sensitive to thienopyridine treatment), whose 
results are expressed as P2Y12 Reaction Units (PRU), by 
using ADP as agonist and PGE
1
 as suppressor of intracellular 
free calcium levels for diminishing the nonspecific influence 
of the ADP-binding to P2Y1 receptors. The VerifyNow system 
showed a moderate agreement with other platelet function 
tests. The assessment of the sensitivity and specificity of the 
method and the definition of a cut-off value for classifying 
patients at high risk of MACE and not responsive to acetyl-
salicylic acid (ASA) or thienopyridines have been debated and 
different laboratories and clinical studies have reported the 
clinical value of this system.70–77 Recently, in surgical settings, 
the use of the VerifyNow system in patients on antiplatelet 
agents has been expanding for attempting to predict postop-
erative hemorrhage.78,79
Plateletworks system
This system is a WB POC assay based on the measurement 
of platelet count before and after aggregation. This system 
consists of the Plateletworks aggregation kit formed by 
EDTA tubes and citrate tubes implemented with agonists 
(ADP or AA) and the Ichor blood counter (Helena Labora-
tories, Beaumont, TX, USA).80 The Plateletworks method 
matches the platelet count assessed in the control sample 
(EDTA tube) with those obtained after aggregation in citrate 
blood with ADP or AA (citrate tube plus agonist). Since 
platelets aggregate, the fall in their count measured in citrate 
tubes is the extent of activated platelets that have aggregated 
themselves. This rapid test does not need any manipulation 
of blood sample, and results are ready in minutes. A disad-
vantage of the test is that it should be performed within a 
few minutes of blood sampling. The need for this strict time 
interval has relegated this analysis to restricted operating 
areas such as cardiac surgery and cardiac operating room. 
Relationships between  Plateletworks and LTA,  VerifyNow 
system and  Thromboelastography have been reported as vali-
dation test for monitoring antiplatelet therapy.81–83 In acute 
care condition, Plateletworks shows the clinical value of 
giving information about both platelet count and function.84,85 
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Nevertheless, it is still under consideration and has not been 
reported to predict clinical outcomes.
Tests based on platelet adhesion  
under shear stress
The Platelet Function Analyzer –  
PFA-100/innovance PFA-200
The Platelet Function Analyzer – PFA-100/Innovance  PFA-200 
is a PFT that uses a device called the PFA-100 or the new 
available and updated Innovance PFA-200 (Siemens, Munich, 
Germany). At the beginning, PFA-100 has been considered 
as the standardization of BT.86,87 The method is based on the 
property of platelets to adhere upon shear stress conditions and 
aggregate in consequence of agonist presence in the system. 
This methodology is considered a POCT that assesses platelet 
function in WB using appropriate cartridges in which primary 
hemostasis is simulated.88–90 Two different test-cartridges 
containing either collagen (C) plus ADP – CADP cartridge – 
or collagen plus epinephrine (EPI) – CEPI cartridge – are 
available. Within the cartridge, the citrated WB is drawn at a 
high shear stress rate through a capillary that has at its end a 
collagen-coated membrane, in which a defined microscopic 
aperture (147 µm) is present, filled with either ADP or EPI. 
A platelet clot, which fills the hole, occurs because of shear 
stress and agonists. The time taken by platelets to occlude the 
orifice and to block the WB flow is defined as closure time 
(CT), a measure of overall platelet-related hemostasis. The CT 
is as much prolonged as the platelets are able to act.
The use of two different assay cartridge allows to differenti-
ate platelet defects due to intrinsic or platelet defects (prolonged 
times of CADP cartridge alone or plus CEPI cartridge) such 
as VW defects or Bernard–Soulier syndrome or Glanzmann’s 
thromboasthenia from those due to antiplatelet therapy with 
ASA (prolonged time of CEPI cartridge).70,90–93 In comparison 
with BT test, this assay has been shown to be more sensitive,70,89 
especially for diagnosis of VWD and platelet function defects.91 
Recently, a third diagnostic, the new Innovance cartridge, sen-
sitive to the thienopyridine therapy, has become available, but 
information on its clinical value is poor and limited.94
The PFA-100 is sensitive to many variables that influ-
ence platelet function – prolonging the CT – as well as low 
platelet count and hematocrit, conditions associated with 
thrombocytopathies. Thus, the clinicians should take these 
limitations into account. On the other hand, factors such as 
high levels of VWF, fibrinogen, or erythrocytes have been 
reported to shorten CEPI CT.95,96 In addition, a short CEPI 
CT could reveal high residual platelet reactivity despite aspi-
rin therapy, thereby predicting the risk of thromboembolic 
events.97,98 Indeed it has been demonstrated in ACS patients 
on ASA treatment that a high concordance exists between 
LTA and the PFA-100 CEPI test, giving significant negative 
predictive value to the PFA system.65 In addition, PFA CEPI 
CT shortened results were demonstrated to be a significant 
and independent predictor of MACEs in patients with acute 
myocardial infarct (AMI) undergoing primary PCI.99–101 In 
patients undergoing different kinds of elective surgeries, the 
assessment of platelet dysfunction with PFA-100 may pro-
vide useful information for postoperative blood transfusion 
management.102,103 Especially in cardiac surgery, PFA meth-
odology showed a high predictive value of platelet function 
for management of intra- and postoperative blood loss.104–107 
In patients with biventricular assist device implantation, on 
treatment with clopidogrel, the use of CADP diagnostics for 
monitoring the degree of platelet inhibition allowed them 
to undergo transplantation without major blood loss.108 In 
addition, prolonged CADP CTs were found be independent 
risk factors for postpartum hemorrhage (PPH) severity and 
were significantly related to menorrhagia.109,110 Presurgical 
prolonged CTs corrected with 1-deamino-8-d-arginine vaso-
pressin (DDAVP), ie, desmopressin treatment, made it pos-
sible to keep unchanged the quantity of postoperative blood 
transfusions with respect to those provided to patients with 
normal presurgical CTs.102
It has been recommended that the PFA system be employed 
as a screening tool integrated into a panel of existing tests.28,38 
This assay is characterized by a high negative predictive value: 
when a normal CT result is found in a suspected platelet 
disease, further PFT should not be performed.5
iMPACT: Cone and Plate(Let) Analyzer
IMPACT: Cone and Plate(Let) Analyzer (Image Analysis 
Monitoring Platelet Adhesion Cone and Plate Technology) 
(CPA) (DiaMed, Cressier, Switzerland) is a novel and inno-
vative POC test that fully assesses platelet function by using 
an automatic and computerized system that evaluates in vitro 
primary hemostasis.111 The test is based on the in vitro activa-
tion and adhesion of platelets that lie all over a standardized 
plate covered by a substrate of polystyrene. The shear stress 
force is impressed to platelets by the spinning of a cone on 
the plate. Citrated WB is used in the system that is formed by 
the reaction device – cone and plate – an automatic staining 
device and image analysis software. After automated stain-
ing, the percentage of the well surface covered by platelet 
aggregates – representing platelet adhesion – and the  average 
size of the aggregates (per µm2) – representing platelet 
 aggregation – are measured.
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This system is highly dependent on plasma. This 
instrument methodology could be a consistent system for 
the diagnosis of platelet defects. Moreover, the addition of 
the agonists AA and ADP in the system has made it pos-
sible to monitor and evaluate the efficacy of dual antiplatelet 
therapy.112,113 However, additional studies should be under-
taken to assess its possible role in the diagnosis of inherited 
or acquired platelet dysfunctions.
The global thrombosis test
The global thrombosis test (GTT) (Montrose Diagnostics Ltd, 
London, UK) is a recent test that assesses platelet function 
in a manner close to physiological conditions because this 
technique is performed by using native nonanticoagulated 
WB, without adding agonists.114–116 The principle on which it 
is based is platelet activation due to high shear stress, oppor-
tunely provoked, similar to that in coronary artery stenosis. In 
this new system, the WB flows into a plastic tube that holds 
a conical part in which two ceramic balls are placed. The 
complete occlusion of the tube lumen due to the presence of 
the spheres is prevented by the flat segment created along the 
inner wall of the tube. WB flows under the force of gravity 
through the four narrow gaps of the first ball where high shear 
stress activates platelets. In the space underlying the first ball, 
low shear and turbulent flow support platelet aggregation. The 
platelet plug occludes the gaps at the level with second ball at 
the end tube and the WB exits always more slowly in the form 
of drops. In the first phase, the occlusion of the tube system, 
expressed as occlusion time (OT) in seconds, occurs. The 
time of interval (d) between two consecutive drops is recorded 
until an arbitrary endpoint (d $15 seconds) is reached. In the 
second phase, the blood flow resumes at the end of the tube 
owing to spontaneous lysis of occlusion expressed as lysis 
time (LT) in seconds. This rapid POC test provides results 
on the patient’s thrombotic status, and it is thus employed 
in acute and critical care settings, as well as in more general 
screening.116–118 The evaluation of GTT results in association 
with clinical outcomes is still in progress. However, because 
GTT presents a double clinical value, this test might play a role 
in the future for the assessment of platelet function.115,119
Platelet function methods in conjunction 
with viscoelastic methodologies
TeG platelet mapping system  
and ROTeM platelet test
Thromboelastography and thromboelastometry are method-
ologies employed for the global assessment of the hemostatic 
process. These assays investigate the entire development 
of clot formation and are based on the analysis of WB 
modifications in viscoelastic forces during the clotting forma-
tion. Indeed, the potential of this methodology is related to 
assessing the extent of platelet count and function, clotting, 
and fibrinolytic activation.120 In these tests, platelets play all 
their functional roles in hemostasis: thrombin generation, 
clot formation, clot retraction, and lysis.
At present, three principal systems are available: 
 Thromboelastography, performed on “old” renewed devices 
(TEG; Haemoscope, IL, USA), Thromboelastometry, for-
merly called Rotational Thromboelastography, performed 
on a new device (ROTEM; TEM Int, Munich, Germany), 
and Sonoclot analysis performed on a new device (Sonoclot 
Signature; Sienco, CO, USA). The principle underlying the 
method for TEG and ROTEM consists in a rotating system 
inclusive of a pin suspended by a torsion wire in a cup. In the 
WB sample, owing to the addition of reagents and the shear 
stress of the rotating system, the forming clot entraps the pin 
promoting a motion that increases as the clot strengthens and 
decreases as the clot lyses. In the Sonoclot device in the cup, 
the pin is moved up and down at an ultrasonic rate.121
The in vitro addition of specific reagents and activator to 
WB provokes the hemostatic activation followed by modi-
fications in hematic viscoelastic forces: the entire process 
is instantly recorded during all clotting formation and also 
visualized in a typical curve. Different tests are available 
depending on the reagent used: tissue factor for extrinsic 
pathway, different activators (glass, silica, kaolin, ellagic 
acid) for intrinsic pathway. Those additional compounds 
are used for revealing particular aspects of hemostasis: 
 heparinase for evaluating the degree of anticoagulation of 
heparin, aprotinine for evaluating the activation of fibrinoly-
sis, and antiplatelet agents (cathepsin G or GPIIb/IIIa antago-
nists) for eliminating the contribution of platelets to clotting 
formation. For each test, different parameters, indicating the 
different steps of hemostasis, are shown after the recogni-
tion and computation by the integrated software detection: 
K index (TEG) and Clot Formation Time (CFT, ROTEM) 
recognizes platelet function, Angle alpha (for both) indicates 
the rate of fibrin-formation, Maximal Amplitude (MA, TEG) 
and Maximum Clot Firmness (MCF, ROTEM) indexes show 
the platelet contribution to clot formation. In addition, by the 
selective activation of extrinsic pathway without and with 
antiplatelet agents (ie, clotting by fibrinogen alone), it is pos-
sible to evaluate the extent of platelet contribution to the clot 
formation. Because all this instrumentation promptly delivers 
a graphic representation of clot formation and lysis, they are 
now used as POC devices in different clinical settings such as 
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cardiac surgery, liver transplantation, obstetrical emergency, 
and trauma center.122–135 To date, the clinical value of this 
technology has consisted in offering a predictive evaluation 
of the risk of increased postoperative bleeding. For surgical 
and emergency settings, different studies have documented 
flow charts in which are reported when to use these systems 
and how to interpret their results in patients at risk of bleed-
ing, such as those on antiplatelet treatment. Actually, it has 
now been identified how the use of the different parameters 
provided by these tests may be predictors of both postopera-
tive bleeding and blood product use.136–138
Currently, new applications for the study of platelet 
function are available. The TEG platelet mapping system is 
a modification of the original TEG and has been developed 
for monitoring antiplatelet therapy.139–142 First, a kaolin-acti-
vated test is performed to evaluate the maximal hemostatic 
activity. Second, a test in the presence of reptilase and Factor 
XIIIa (activator F) is used to produce a cross-linked fibrin 
clot. The addition of ADP or AA stimulates differentially 
the role of platelet ADP or TXA2 receptors in clot forma-
tion. The effect of therapy with aspirin (AA addition) or 
thienopyridines (ADP addition) is evaluated by comparing 
the TEG kaolin-activated test curve with the AA or ADP-
stimulated TEG curve. The method has been shown to be 
reliable with low analytical variation.143,144 However, further 
large prospective studies should be performed in order 
to define the possible role of these devices in monitoring 
antiplatelet therapy.
On the other hand, the ROTEM platelet system is a 
new module that could be added to the ROTEM. A WB 
aggregometer as an integrated module has been added to the 
ROTEM system. This allows a deeper analysis of the primary 
hemostasis of the patient along with that of coagulation. 
The measurement is based on true impedance aggregometry 
(such as the MEA system), which allows the measurement 
of platelet aggregation in WB samples. The software for the 
analysis data is the same as of the ROTEM system. In this 
manner, the platelet function analysis is visualized together 
with the thromboelastometric measurements, altogether 
on the same screen; in fact, the two different assays (both 
thromboelastometry and platelet aggregometry) can be 
run together in the same time on the same system. Some 
characteristics of the ROTEM platelet are similar to those 
of MEA, such as single-use cuvettes, time of test, measured 
parameters, and agonists used. Because the availability of 
this assay is very recent – it goes back to a few months 
ago – only a few data are currently available about its labo-
ratory and clinical value.145
Platelet analysis based on flow cytometry
Flow cytometry (FC) is a technique of rapidly measuring 
specific characteristics of many different cells such as plate-
lets, measuring the cell size, and granularity. FC analysis of 
platelets may offer information on their functional status in 
vivo, and this technique encompasses multiple assays for 
several purposes such as the assessment of the activation state 
(platelet membrane-associated IgG), evaluation of throm-
bopoiesis, diagnosis of specific disorders, and antiplatelet 
agent monitoring.146–148
This analysis is based on the optical and fluorescence 
evaluation of physical – such as size and internal complexity – 
and antigenic properties of platelets, ie, determination of 
surface receptors including conformational changes related 
to the receptor activation, platelet granule secretion, presence 
of platelet aggregates, and leukocyte–platelet aggregates.149 
It consists of the measurement of antibodies conjugated 
to fluorescent dyes that may bind specific proteins on cell 
membranes or inside cells, revealing their presence. A light 
source, crossing labeled platelets, excites to a higher energy 
state the fluorescent molecules of dyes. When the fluoro-
chromes return to a resting state, they emit light energy at 
different wavelengths. The use of multiple fluorochromes 
with similar excitation wavelengths, but different emission 
wavelengths (or “colors”), allows several cell properties to 
be measured simultaneously. Different fluorochromes such 
as fluorescein isothiocyanate (FITC) or phycoerythrin (PE) 
can be used, but also a specie-specific secondary antibody 
coupled to a fluorochrome can be employed to recognize a 
primary antibody linked to surface antigens.15 In the WB, 
the use of a double labeling binding allows the identifica-
tion of platelets, platelet microparticles, or mixed cell 
aggregates.150–152 The results of FC are represented in the 
form of histograms with mean fluorescence intensity (MFI) 
plotted against cell number.
A plethora of platelet defects and features can be investi-
gated by FC. Indeed, it can be a useful tool for the diagnosis 
of inherited (ie, Bernard–Soulier syndrome, Glanzmann’s 
thrombasthenia) or acquired platelet dysfunctions (ie, HIT) 
and storage pool disease. As this analysis is able to assess 
platelet function defects in patients with very low platelet 
count, it is considered the test of choice to define the presence 
of thrombocytopathy in a thrombocytopenic patient.9 In this 
regard, an FC for the diagnosis of thrombocytopenic disor-
ders has been developed to measure reticulated platelets.153 
In addition, FC allows one to recognize the procoagulant 
capacity and activation state of platelets (eg, in the setting 
of acute coronary syndromes or cardiopulmonary bypass), 
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by highlighting the expression of phosphatidylserine on 
activated platelet membranes using labeled annexin V.154
Different steps in intracellular signal transduction can be 
investigated by FC. Indeed, the intracellular quantification of 
Vasodilator Stimulated Phosphoprotein (VASP) phosphoryla-
tion by FC is the most used method for monitoring the efficacy 
of antiplatelet drugs.155,156 Finally, FC is used to evaluate the 
state of stored platelets in blood banks. For example, it is pos-
sible to assess the platelet activation state and identify leuko-
cyte contamination of platelet concentrates for the evaluation 
of the efficacy of platelet transfusion.157–159
FC has many advantages, such as the use of small volumes 
of blood samples and the analysis of platelets in physiological 
milieu (WB). On the other hand, FC analysis is an expensive 
test, requiring specialized operators and devices, and the pre-
analytical phase can be affected by the delicate preparation 
prone to artifact unless carefully prepared.8,9
evaluation of Thromboxane metabolites
In physiological conditions, when platelets are stimulated 
by agonists, TXA2 is rapidly synthesized and released from 
platelets at the site of vascular injury. TXA2 amplifies the 
platelet activation, recruits additional platelets to the site of 
clot formation, and induces vasoconstriction, accelerating the 
hemostasis process.160 TXA2 is the major product of the plate-
let metabolism of AA. AA, released from platelet membrane 
phospholipids via phospholipase A2 (PLA2), is converted 
in the endoperoxides, prostaglandin G2 (PGG2) and PGH2, 
via cyclooxygenase-1 (COX-1) and finally transformed into 
TXA2 by thromboxane synthase. TXA2 is rapidly trans-
formed by hydrolysis into TXB2, a biologically inactive and 
stable product.160,161 TXB2 is excreted unchanged in urine in 
a small percentage being prevalently transformed into two 
major metabolites: 2,3-dinor-TXB2 and in  11-dehydro-TXB2 
by β-oxidation and dehydration, respectively. These metabo-
lites circulate in the plasma at low concentrations and are 
excreted in urine, and it has been established that 11-dehydro-
TXB2 is more abundant in urine than 2,3-dinor-TXB2.162,163 
In inflammatory  conditions, TXA2 can be produced by 
other biochemical pathways independently from platelets 
and extraplatelet sources of TXA2 can become relevant.164 
Conversely, ASA interfering with COX-1 activity causes a 
decrease in the concentration of serum TXB2 and urinary 
11-dehydro-TXB2.165,166
The measurement of TXA2 metabolites allows evaluation 
of the activation state of platelets.8,9 Serum and urine TXB2 
metabolites concentrations are related to the entity of TXA2 
biosynthesis, and their dosage may be useful to assess platelet 
function in different diseases, to detect defects of thromboxane 
production, and to monitor aspirin therapy.8,9,167,168 Different 
ligand-binding assays based on the binding of the analyte to 
specific receptors by using different detection methods can 
be used to assess serum TXB2 and urinary 11-dehydro-TXB2 
concentration, such as: 1) the “old” radioimmunoassays 
(RIA) or immunoradiometric assays (IRMA) that are now 
outdates;169–171 2) enzyme-linked immunoassays (ELISA) that 
are now the most commonly utilized assays.172,173
Future perspective
Different methodologies for the assessment of platelet (dys)
function in order to screen different idiopathic or acquired 
pathological conditions – hemorrhagic and/or prothrombotic 
status – are currently available. At present, platelet tests are 
mostly used, thanks to the work put into the standardization 
of these tests, in the drawing up flowchart and to the introduc-
tion of primary hemostasis POCT. These available tests allow 
either the study of global platelet function or the evaluation of 
particular aspects of platelet activation. Primary hemostasis 
POC tests simultaneously may assess in vitro platelet adhesion 
and aggregation; platelet aggregation analysis is inclusive of 
platelet secretion and aggregation phenomena. In particular, 
in WB platelet aggregation, the role of other blood cells is 
considered; viscoelastic methods analyzing global hemostasis 
are able to individuate platelet dysfunction (Tables 1 and 2). 
Despite this versatility and their important clinical value, 
platelet assays pertaining to the same category (eg, those based 
on platelet aggregometry) are again affected by a wide range 
of methodological aspects. The numerous conditions involved 
in them cause an interlaboratory variability of results and can 
delay a clear standardized procedure. This major gap is partly 
overcome by the introduction of platelet function POCT, 
which presents a basilar standardized procedure. In light of 
this, a new platelet adhesion test using microfluidic devices, 
for example, a biochip containing several different adhesions, 
is under  evaluation.174,175 Now, platelet spreading tests, using 
fluorescence microscopy or scanning electron microscopy, 
are frequently employed.176 On activation, platelets are able 
to release or express several compounds such as ATP, ADP, 
5-HT, CXCL12, CD34, P-selectine, or thromboxanes, which 
may be assessed by using different methodologies such as 
immunological assay, High-performance liquid chromatog-
raphy, fluorescence microscopy, or flow cytometry.28,177,178 
The major drawback of the application of these assays in 
clinical practice is the scarcity and high variability of clini-
cal and laboratory data and the absence of clear indications 
or guidelines for the correct use of such tests. Either for the 
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study of global or single step of platelet function or for the 
definition of the clinical value of new platelet biomarkers, new 
or renewed platelet assays with high sensitivity and specificity 
are considered necessary, especially for routine laboratory 
analysis. In the future, it is desirable that specific, standardized, 
more rapid and easy tests – whose clinical value has been well 
defined – are available.
Conclusion
To date, the effort of translating the different PFTs as diag-
nostic tools for evaluating bleeding disorders and monitoring 
antiplatelet therapies is in progress. Actually, the available 
platelet function POCT is making possible the institution of 
platelet tests in laboratories and intensive care units, allow-
ing their use in different clinical settings such as inherited 
bleeding disorders, cardiovascular intensive care, trauma 
coagulopathy, liver transplantation, and obstetric care for the 
prediction of bleeding. Similarly, the use of these POC tests 
could be extended not only at the bedside in critical areas 
outside of the specialized laboratory, but also in centralized 
and satellite laboratories. Indeed, the upgrading of the WB 
test, such as MEA, or platelet mapping or the new ROTEM 
platelet device, may guide clinicians in making the correct 
diagnosis of bleeding risk or in properly tailoring the anti-
platelet therapy directly in pre-/postoperative care.
Nevertheless, for the amelioration of the ongoing stan-
dardization of LTA, new procedures were reported in 2010, 
2011, and 2013.37–39 For this, PRP or WB platelet aggrego-
metry by using new systems might be realized into routine 
laboratories. Because the availability of platelet tests is an 
important improvement, the drafting of validation procedures 
and the study of reliability and quality control testing of PFT 
are becoming an increasingly important issue.
In conclusion, the new POCTs available may be consid-
ered useful supplements to the existing well-known platelet 
function tests, but further prospective studies are necessary 
to define the applications of these tests. In the future, the 
improvements in the study of platelet genome and proteome 
may encompass knowledge of platelet function testing with 
a noteworthy impact on the diagnosis and management of 
patients affected by hemorrhagic or thrombotic defects.
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